Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer

Keyphrases

• Risk Model 100%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 100%
• Metastatic Burden 100%
• Overall Survival 71%
• Predictive Ability 42%
• Hemoglobin Level 28%
• Low Hemoglobin 28%
• Disease Burden 28%
• High Burden 28%
• Low Burden 28%
• Liver Metastasis 14%
• Japan 14%
• Multivariate Analysis 14%
• Clinical Application 14%
• Progression-free Survival 14%
• Validation Cohort 14%
• Disease Score 14%
• Retrospective Observational Study 14%
• Androgen Deprivation Therapy 14%
• Clinical T Stage 14%
• Extent of Disease 14%
• Gleason Grading 14%
• Prognosis Estimation 14%
• Gleason Grade Group 14%
• Discriminatory Ability 14%

Medicine and Dentistry

• Overall Survival 100%
• Prostate Cancer 100%
• Gleason Score 40%
• Disease Burden 40%
• Liver Metastasis 20%
• Disease 20%
• Multivariate Analysis 20%
• Progression Free Survival 20%
• Observational Study 20%
• Decision Making 20%
• Androgen Deprivation Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Overall Survival 100%
• Prostate Cancer 100%
• Disease 60%
• Gleason Score 40%
• Liver Metastasis 20%
• Progression Free Survival 20%
• Androgen 20%
• Observational Study 20%